Q-omics provides the consensus-scored ZNF25 profile across patient tissues and cancer cell-line models. ZNF25 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZNF25 is differentially expressed in 14, with the highest sampling consensus in LUSC. Additionally, ZNF25 RNA expression shows 21,963 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, LUSC, and PDAC as cancer lineages where ZNF25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF25 survival associations across molecular data types. ZNF25 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF25 RNA expression–survival associations across cancer types. High ZNF25 expression shows unfavorable associations in SCLC, but favorable associations in SKCM, LUAD, KIRC, HNSC and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZNF25 RNA expression.
This table summarizes ZNF25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF25 shows lower tumor expression in LUSC, LUAD, THCA, KICH and UCEC and higher tumor expression in KIRC. The LUSC box plot shows higher ZNF25 RNA expression in normal versus tumor tissue (log2 FC = −1.368, t-test p < 0.001).
This table shows molecular features associated with ZNF25 in patient tissues and cancer cell lines. In patient samples, ZNF25 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
